Propranolol attenuates hemorrhage and accelerates wound healing in severely burned adults. 2015

Arham Ali, and David N Herndon, and Ashish Mamachen, and Samir Hasan, and Clark R Andersen, and Ro-Jon Grogans, and Jordan L Brewer, and Jong O Lee, and Jamie Heffernan, and Oscar E Suman, and Celeste C Finnerty
Department of Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555, USA. arhali@utmb.edu.

BACKGROUND Propranolol, a nonselective β-blocker, exerts an indirect effect on the vasculature by leaving α-adrenergic receptors unopposed, resulting in peripheral vasoconstriction. We have previously shown that propranolol diminishes peripheral blood following burn injury by increasing vascular resistance. The purpose of this study was to investigate whether wound healing and perioperative hemodynamics are affected by propranolol administration in severely burned adults. METHODS Sixty-nine adult patients with burns covering ≥ 30% of the total body surface area (TBSA) were enrolled in this IRB-approved study. Patients received standard burn care with (n = 35) or without (control, n = 34) propranolol. Propranolol was administered within 48 hours of burns and given throughout hospital discharge to decrease heart rate by approximately 20% from admission levels. Wound healing was determined by comparing the time between grafting procedures. Blood loss was determined by comparing pre- and postoperative hematocrit while factoring in operative graft area. Data were collected between first admission and first discharge. RESULTS Demographics, burn size, and mortality were comparable in the control and propranolol groups. Patients in the propranolol group received an average propranolol dose of 3.3 ± 3.0 mg/kg/day. Daily average heart rate over the first 30 days was significantly lower in the propranolol group (P < 0.05). The average number of days between skin grafting procedures was also lower in propranolol patients (10 ± 5 days) than in control patients (17 ± 12 days; P = 0.02), indicative of a faster donor site healing time in the propranolol group. Packed red blood cell infusion was similar between groups (control 5.3 ± 5.4 units vs. propranolol 4.4 ± 3.1 units, P = 0.89). Propranolol was associated with a 5 to 7% improvement in perioperative hematocrit during grafting procedures of 4,000 to 16,000 cm(2) compared to control (P = 0.002). CONCLUSIONS Administration of propranolol during the acute hospitalization period diminishes blood loss during skin grafting procedures and markedly improves wound healing in severely burned adults. As burn patients require serial surgical interventions for motor and cosmetic repair, restricting blood loss during operative intervention is optimal.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D002056 Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like. Burn
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D014945 Wound Healing Restoration of integrity to traumatized tissue. Healing, Wound,Healings, Wound,Wound Healings

Related Publications

Arham Ali, and David N Herndon, and Ashish Mamachen, and Samir Hasan, and Clark R Andersen, and Ro-Jon Grogans, and Jordan L Brewer, and Jong O Lee, and Jamie Heffernan, and Oscar E Suman, and Celeste C Finnerty
September 2017, Burns : journal of the International Society for Burn Injuries,
Arham Ali, and David N Herndon, and Ashish Mamachen, and Samir Hasan, and Clark R Andersen, and Ro-Jon Grogans, and Jordan L Brewer, and Jong O Lee, and Jamie Heffernan, and Oscar E Suman, and Celeste C Finnerty
September 2014, The American journal of pathology,
Arham Ali, and David N Herndon, and Ashish Mamachen, and Samir Hasan, and Clark R Andersen, and Ro-Jon Grogans, and Jordan L Brewer, and Jong O Lee, and Jamie Heffernan, and Oscar E Suman, and Celeste C Finnerty
November 2022, The journal of trauma and acute care surgery,
Arham Ali, and David N Herndon, and Ashish Mamachen, and Samir Hasan, and Clark R Andersen, and Ro-Jon Grogans, and Jordan L Brewer, and Jong O Lee, and Jamie Heffernan, and Oscar E Suman, and Celeste C Finnerty
December 2017, JPMA. The Journal of the Pakistan Medical Association,
Arham Ali, and David N Herndon, and Ashish Mamachen, and Samir Hasan, and Clark R Andersen, and Ro-Jon Grogans, and Jordan L Brewer, and Jong O Lee, and Jamie Heffernan, and Oscar E Suman, and Celeste C Finnerty
December 2009, BMB reports,
Arham Ali, and David N Herndon, and Ashish Mamachen, and Samir Hasan, and Clark R Andersen, and Ro-Jon Grogans, and Jordan L Brewer, and Jong O Lee, and Jamie Heffernan, and Oscar E Suman, and Celeste C Finnerty
November 2000, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen,
Arham Ali, and David N Herndon, and Ashish Mamachen, and Samir Hasan, and Clark R Andersen, and Ro-Jon Grogans, and Jordan L Brewer, and Jong O Lee, and Jamie Heffernan, and Oscar E Suman, and Celeste C Finnerty
September 1999, The Journal of investigative dermatology,
Arham Ali, and David N Herndon, and Ashish Mamachen, and Samir Hasan, and Clark R Andersen, and Ro-Jon Grogans, and Jordan L Brewer, and Jong O Lee, and Jamie Heffernan, and Oscar E Suman, and Celeste C Finnerty
January 1999, The Journal of trauma,
Arham Ali, and David N Herndon, and Ashish Mamachen, and Samir Hasan, and Clark R Andersen, and Ro-Jon Grogans, and Jordan L Brewer, and Jong O Lee, and Jamie Heffernan, and Oscar E Suman, and Celeste C Finnerty
October 2010, Shock (Augusta, Ga.),
Arham Ali, and David N Herndon, and Ashish Mamachen, and Samir Hasan, and Clark R Andersen, and Ro-Jon Grogans, and Jordan L Brewer, and Jong O Lee, and Jamie Heffernan, and Oscar E Suman, and Celeste C Finnerty
May 2011, Journal of leukocyte biology,
Copied contents to your clipboard!